3851-47-6

Usage

Uses

Used in Organic Synthesis:
(4-Bromophenyl)(4-fluorophenyl)Methanol is used as a building block in the production of pharmaceuticals, agrochemicals, and other specialty chemicals. Its versatile reactivity allows it to be a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, (4-Bromophenyl)(4-fluorophenyl)Methanol is used as a key intermediate in the development of new drugs. Its unique structure and reactivity contribute to the creation of novel compounds with potential therapeutic applications.
Used in Medicinal Chemistry:
(4-Bromophenyl)(4-fluorophenyl)Methanol is utilized as a reagent in various chemical reactions, such as Suzuki-Miyaura and Sonogashira coupling reactions, which are essential for the synthesis of complex organic molecules with potential medicinal properties.
Used in Drug Development:
Due to its potential biological activities and pharmacological properties, (4-Bromophenyl)(4-fluorophenyl)Methanol is being studied for its possible use as a drug candidate in the future. Its unique structural features and reactivity make it a promising starting point for the development of new therapeutic agents.
Used in Agrochemical Production:
In the agrochemical industry, (4-Bromophenyl)(4-fluorophenyl)Methanol is employed as a building block for the synthesis of various agrochemicals, such as pesticides and herbicides, that are essential for agricultural productivity and crop protection.

Upstream product

• 2069-41-2 (4-bromophenyl)-(4-fluorophenyl)methanone 
• 1122-91-4 4-bromo-benzaldehyde 
• 352-13-6 4-flourophenylmagnesium bromide 
• 403-43-0 4-fluorobenzoyl chloride 
• 106-37-6 1.4-dibromobenzene 
• 459-57-4 4-fluorobenzaldehyde 
• 108-86-1 bromobenzene 

Downstream Products

• 96122-71-3 1-{2-[(4-Bromo-phenyl)-(4-fluoro-phenyl)-methoxy]-ethyl}-pyrrolidine 
• 51535-40-1 (4-Bromo-phenyl)-(4-fluoro-phenyl)-acetic acid 
• 96122-88-2 4-bromo-4'-fluorobenzhydryl 2-bromoethyl ether 
• 181207-58-9 4-[4-(4-fluorobenzyl)phenyl]-1,2,3,6-tetrahydropyridine 
• 181207-59-0 4-[4-(4-fluorobenzyl)phenyl]piperidine 
• 181207-49-8 N-tert-butoxycarbonyl-4-[4-(4-fluorobenzyl)phenyl]-4-piperidinol 
• 202716-35-6 4-[4-(4-fluorobenzyl)phenyl]-4-piperidinol 
• 202716-26-5 N-benzyl-4-[4-(4-fluorobenzyl)phenyl]-4-piperidinol 
• 96122-81-5 1-{2-[(4-Bromo-phenyl)-(4-fluoro-phenyl)-methoxy]-ethyl}-4-o-tolyl-piperidin-4-ol 
• 96122-83-7 1-<2-(4-bromo-4'-fluorobenzhydryloxy)ethyl>-4-(4-fluorophenyl)piperidin-4-ol 
• 96122-92-8 1-<2-(4-bromo-4'-fluorobenzhydryloxy)ethyl>-4-(3-<2-(4-bromo-4'-fluorobenzhydryloxy)ethyl>-2-oxo-benzimidazol-1-yl)-1,2,3,6-tetrahydropyridine 
• 17100-44-6 4-bromo-4α-fluorodiphenylmethane 
• 96122-67-7 N,N-dimethyl-2-<1-(4-bromophenyl)-1-(4-fluorophenyl)ethoxy>ethylamine 

Relevant academic research and scientific papers

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. They have the following structure: Formula (I).

Synthesis and biological evaluation of new 4-arylpiperidines and 4-aryl-4-piperidinols: dual Na+ and Ca2+ channel blockers with reduced affinity for dopamine D2 receptors

A series of novel 4-arylpiperidines and 4-aryl-4-piperidinols (2a-f, 3a-f and 4a-f) was synthesized and evaluated for blocking effects on both neuronal Na+ and T-type Ca2+ channels and binding affinity for dopamine D2 receptors. Most of the compounds blockaded both ion channels with potency greater than or equal to flunarizine 1a which was adopted as a reference standard. In addition, these compounds had significantly reduced affinity for dopamine D2 receptors which is common in this class of structure. Compounds 2a-f, 3a-f and 4a-f exhibited potent anticonvulsant effects following systemic (ip) administration on audiogenic seizures in DBA/2 mice, indicating their excellent brain permeability. The neuroprotective activity of 2a, 3a and 4a was also assessed in a transient middle cerebral artery occlusion (MCAO) model. These compounds significantly reduced neuronal damage without affecting ischemic hyperthemia, while flunarizine 1a produced only minor reductions. In particular, 4a had 1.7-fold the potency in this MCAO method but only 1/20 the affinity for dopamine D2 receptor of 1a. The superposition of 2a, 3a and 4a on the basis of analyses of systematic conformation and similar structure has revealed that the cinnamyl, phenacyl and phenoxypropanol groups are likely to be structurally and biologically equivalent. Moreover, the superposition of 2a and 2f shows that diphenyl ether and biphenyl groups occupy a similar space, suggesting that both groups act as a bioisostere for the blockade of ion channels; however, this is not the case for dopamine D2 receptors since only biphenyl compounds such as 2f had high affinitity similar to flunarizine 1a. Compound 4a (SUN N5030) has a good pharmacological profile and may be useful in the alleviation and treatment of ischemic diseases. Copyright